// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

Determining the unmet survivorship needs in patients with head and neck cancer: A prospective, longitudinal study.

Meredith Elana Giuliani - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Validation of MAF biomarker for response prediction to adjuvant bisphosphonates in 2 clinical trials: AZURE and NSABP-B34.

Alexander H. G. Paterson - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Clodronate disodium

The comparative effectiveness of glasdegib in combination with low-dose cytarabine versus azacitidine by bone marrow blasts counts among patients with newly-diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy.

Sophie van Beekhuizen - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Vidaza

In vitro and in vivo characterization of MDNA11: A long-acting “beta-only” IL-2 superkine in syngeneic mice tumor models and nonhuman primates.

Moutih Rafei - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

MDNA11

Reimbursement recommendations for cancer drugs supported by phase II evidence in Canada.

Regina Li - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

SAVOIR: A phase III study of savolitinib versus sunitinib in pts with MET-driven papillary renal cell carcinoma (PRCC).

Toni K. Choueiri - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Savolitinib

Quality of life (QOL) for the treatment sequence of abiraterone acetate plus prednisone (AAP) followed by enzalutamide (ENZ) versus the opposite sequence for metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized clinical trial.

Daniel J Khalaf - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

CB-7598

CCTG HN.10: A phase II single-arm trial of elective volume adjusted de-escalation radiotherapy (EVADER) in patients with low-risk HPV-related oropharyngeal squamous cell carcinoma (NCT03822897).

Scott Victor Bratman - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Gut microbiome to predict efficacy and immune-related toxicities in patients with advanced non-small cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy.

Taiki Hakozaki - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

N/A

N/A

An increase in serum choline levels to predict progression-free survival (PFS) in patients (pts) with advanced cancers receiving pembrolizumab.

Geoffrey Alan Watson - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Pembrolizumab

Real-world treatment attrition rates in advanced esophagogastric cancer.

Erica S. Tsang - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Efficacy and toxicity of extending bone modifying agents beyond two years for bone metastases in breast or castrate-resistant prostate cancer patients: A systematic review.

Terry L. Ng - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Discontinuation of tyrosine kinase inhibitor (TKI) therapy in chronic myeloid leukemia in chronic phase (CML-CP) in US clinical practice after guideline updates.

Ehab L. Atallah - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

L-Tyrosine

Outcomes of patients (pts) with metastatic urothelial carcinoma (mUC) following discontinuation of enfortumab-vedotin (EV): Emergence of a new unmet need.

Catherine Curran - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Enfortumab vedotin

Assessing overall patient satisfaction among cancer patients: A radiotherapy survey.

Jo Anne Meng - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Methadone hydrochloride

A population-based study of chronic neutrophilic leukemia in the United States: 2004 to 2015.

Gordon Ruan - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Predictors of and longitudinal assessment of health utility scores in patients with small cell lung cancer using real-world data.

Nathan Kuehne - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Real-world healthcare resource utilization (HRU)/costs associated with venetoclax treatment among chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) patients.

Kerry Anne Rogers - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Venetoclax

A multicenter study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of taxotere/cyclophosphamide-induced febrile neutropenia in patients with early-stage breast cancer.

Mark J. Clemons - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Cyclophosphamide

Reassessing the net health benefit (NHB) of FDA approved cancer drugs with evolution of evidence using the American Society of Clinical Oncology Value Framework (ASCO-VF).

Seanthel Delos Santos - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved